Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 8/20 | 0.66 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | RXRA | P19793 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MPC2 | O95563 | 1/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL163917 | 0.99 | PPARG (0.66) | PPARGCYP3A4RXRAHPGDMPC2 | |
| SCHEMBL8792213 | 0.88 | PPARG (0.52) | PPARGCYP3A4RXRAHPGDMPC2 | |
| SCHEMBL7881745 | 0.87 | PPARG (0.48) | PPARGCYP3A4RXRAHPGDMPC2 | |
| SCHEMBL5805537 | 0.86 | PPARG (0.53) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| SCHEMBL7828079 | 0.85 | PPARG (0.52) | PPARGCYP3A4RXRAHPGDMPC2 | |
| SCHEMBL1220739 | 0.85 | PPARG (0.48) | PPARGCYP3A4RXRAHPGDMPC2 | |
| Hydrochloric Acid SCHEMBL7838999 | 0.85 | PPARG (0.68) | PPARGCYP3A4RXRAHPGDMPC2 | |
| SCHEMBL28002443 | 0.84 | PPARG (0.60) | PPARGCYP3A4RXRAHPGDMPC2 | |
| SCHEMBL1220487 | 0.84 | PPARG (0.47) | PPARGCYP3A4RXRAHPGDMPC2 | |
| SCHEMBL20579732 | 0.84 | PPARG (0.69) | PPARGCYP3A4RXRAHPGDMPC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694646-B1 | PROCESS FOR THE SYNTHESIS OF PIOGLITAZONE HYDROGEN CHLORIDE | RICHTER GEDEON VEGYESZET (HU) | 2007-04-25 | — | — | EP | claimed |
| EP-1694646-A1 | PROCESS FOR THE SYNTHESIS OF PIOGLITAZONE HYDROGEN CHLORIDE | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2006-08-30 | — | — | EP | claimed |
| WO-2005058827-A1 | PROCESS FOR THE SYNTHESIS OF PIOGLITAZONE HYDROGEN CHLORIDE | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2005-06-30 | — | — | WO | claimed |
| WO-2023205683-A2 | TREATMENT OF GASTROINTESTINAL DISEASES | ACLIPSE TWO INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| CN-111514612-B | Method for rapidly splitting pioglitazone hydrochloride racemate by supercritical fluid chromatography | 江苏德源药业股份有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-111514612-A | Method for rapidly splitting pioglitazone hydrochloride racemate by supercritical fluid chromatography | 江苏德源药业股份有限公司 | 2020-08-11 | — | — | CN | disclosed |
| WO-2013034174-A1 | SOLID PREPARATIONS OF PIOGLITAZONE AND GLIMEPIRIDE | ZENTIVA Saglik Ürünleri Sanayi ve Ticaret A.S. (TR) | 2013-03-14 | — | — | WO | disclosed |
| US-20120295952-A1 | TREATMENT OF FILAGGRIN (FLG) RELATED DISEASES BY MODULATION OF FLG EXPRESSION AND ACTIVITY | CURNA, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| EP-2190417-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN SENSITIZER AND INSULIN SECRETAGOGUE | Teva Pharmaceutical Industries Ltd. (IL) | 2010-06-02 | — | — | EP | disclosed |
| JP-2010105943-A | MANUFACTURING METHOD OF 5-{4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL}-2,4-THIAZOLIDINEDIONE HYDROCHLORIDE | TOKUYAMA CORP | 2010-05-13 | — | — | JP | disclosed |
| EP-1682539-B1 | PROCESS FOR PREPARING THIAZOLIDINEDIONES | SANDOZ AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2005049610-A1 | PROCESS FOR PREPARING THIAZOLIDINEDIONES | SANDOZ AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| EP-1514550-A2 | Combinations for diabetes which contain a sulfonylurea, a glitazone and a biguanide | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-16 | — | — | EP | disclosed |
| EP-1128834-A1 | COMBINATIONS FOR DIABETES WHICH CONTAIN A SULFONYLUREA, A GLITAZONE AND A BIGUANIDE | WARNER-LAMBERT COMPANY (US) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027401-A1 | COMBINATIONS FOR DIABETES WHICH CONTAIN A SULFONYLUREA, A GLITAZONE AND A BIGUANIDE | WARNER-LAMBERT COMPANY (US) | 2000-05-18 | — | — | WO | disclosed |
| EP-0610854-B1 | Tablets with improved abrasion resistance and method to produce them | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2000-04-19 | — | — | EP | disclosed |
| EP-0618915-A1 | A REDUCTION METHOD FOR SUBSTITUTED 5-METHYLENE-THIAZOLIDINEDIONES | THE UPJOHN COMPANY (US) | 1994-10-12 | — | — | EP | disclosed |
| EP-0610854-A1 | Tablets with improved abrasion resistance and method to produce them | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-17 | — | — | EP | disclosed |
| WO-1993022445-A1 | A PROCESS FOR PRODUCING PIOGLITAZONE METABOLITE | THE UPJOHN COMPANY (US) | 1993-11-11 | — | — | WO | disclosed |
| WO-1993013095-A1 | A REDUCTION METHOD FOR SUBSTITUTED 5-METHYLENE-THIAZOLIDINEDIONES | THE UPJOHN COMPANY (US) | 1993-07-08 | — | — | WO | disclosed |